Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO Income Before Tax
Profit after all operating and non-operating items but before income tax.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$12.43M, compared with -$6.76M a year earlier. Trailing-twelve-month income before tax was -$42.19M.
Context
- Income before tax grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near -$12.43M or moves back toward the trailing-twelve-month quarterly average of -$10.55M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
Mixed currencies · from the income statement
- Latest · FY2025
- (39.26M) USD
- Year-over-year change
- -60.2%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.26M) | -60.2% |
| FY2024 | 2024-12-31 | (24.51M) | +15.3% |
| FY2023 | 2023-12-31 | (28.93M) | — |
| FY2022 | 2022-12-31 | (23.92M) | -2.3% |
| FY2021 | 2021-12-31 | (23.37M) | — |
Income Before Tax vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -41.0% is the 7th highest of 8, against a peer median of +37.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $56.04M USD | +10.0% | +32.0% | 18.4% | |
| LTM Mar 2026 | $5.47M USD | +111.0% | — | 2.1% | |
| LTM Apr 2026 | -CA$3.35M CAD | +64.9% | — | — | |
| LTM Mar 2026 | -$8.81M USD | +37.4% | — | 17.2% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | -$38.59M USD | -19.3% | — | 205.7% |
| LTM Mar 2026 | -CA$38.87M CAD | -329.6% | — | 14.2% | |
| LTM Mar 2026 | -$42.19M USD | -41.0% | — | — | |
| LTM Mar 2026 | -CA$263.45M CAD | +55.9% | — | 84.7% | |
| Peer median (excluding EPRX.TO) | — | +37.4% | +32.0% | 17.8% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| Gross Profit | (111.53K) | (193.27K) | (158.05K) | (163.47K) | (241.88K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.17M | 17.58M | 21M | 15.17M | 21.51M |
| Selling, General & Admin | 8.2M | 5.81M | 7.37M | 10.92M | 17.1M |
| Operating Expenses | 18.38M | 23.38M | 28.37M | 25.54M | 38.86M |
| Depreciation & Amortization | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| EBITDA | (21.96M) | (22.14M) | (28.16M) | (23.43M) | (38.86M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.47M) | (23.58M) | (27.78M) | (25.71M) | (39.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65.73K | 569.32K | 876.96K | 1.1M | 1.44M |
| Interest Expense | 1.3M | 1.59M | 1.19M | 913.1K | 0 |
| Other Income / Expenses | (4.9M) | (341.09K) | (1.08M) | 1.2M | (155.19K) |
| Income Before Tax | (23.37M) | (23.92M) | (28.93M) | (24.51M) | (39.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | (67.51K) | 1.72K | 19.42K |
| Net Income | (22.99M) | (23.26M) | (28.15M) | (24.28M) | (39.25M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| EPS (Diluted) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.